Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 3:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Rabies Exposure Clear all
Completed Phase 2 Interventional Results available

Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies

NCT03961555
View directory record Official record
Conditions
Rabies
Interventions
SYN023, HRIG (HyperRab), Rabies vaccine
Biological
Lead sponsor
Synermore Biologics Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Gainesville, Florida • Iowa City, Iowa • Milan, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 3, 2026, 3:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Intradermal Administration of PCEC Rabies Vaccine

NCT01044199
View directory record Official record
Conditions
Rabies Prevention, Rabies Exposure
Interventions
PCEC rabies vaccine given intradermally, PCEC rabies vaccine administered intramuscularly
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 3, 2026, 3:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis

NCT02374814
View directory record Official record
Conditions
Rabies
Interventions
Rabies vaccine, Placebo
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2022 · Synced Sep 3, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of a Purified Vero Rabies Vaccine

NCT03145766
View directory record Official record
Conditions
Rabies Virus
Interventions
VRVg 2, VRVg 1, Imovax Rabies, Human Rabies Immunoglobulins (HRIG)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
5
States / cities
Redding, California • San Diego, California • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 3, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen

NCT01877395
View directory record Official record
Conditions
Rabies
Interventions
Purified Vero Rabies Vaccine (VRVg), Imovax® Rabies: inactivated rabies vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
342 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
5
States / cities
Pembroke Pines, Florida • South Miami, Florida • Boise, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Sep 3, 2026, 3:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.

NCT02564471
View directory record Official record
Conditions
Rabies
Interventions
Chloroquine, Atovaquone and Proguanil, Doxycycline, Rabies Vaccine
Drug · Biological
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 60 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 3, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use

NCT01784874
View directory record Official record
Conditions
Rabies
Interventions
Purified Vero Rabies Vaccine (VRVg) - Serum Free, Imovax® Rabies: inactivated rabies vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
408 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
6
States / cities
Redding, California • Sacramento, California • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Sep 3, 2026, 3:53 AM EDT
Terminated No phase listed Observational

Survey of Human Rabies Immune Globulin Safety in Children

NCT05382650
View directory record Official record
Conditions
Rabies, Rabies Human, Rabies Virus Infection, Pediatrics
Interventions
Human rabies immune globulin 300 IU/mL
Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
Up to 17 Years
Enrollment
35 participants
Timeline
2023 – 2025
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 3, 2026, 3:53 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects

NCT02040090
View directory record Official record
Conditions
Rabies
Interventions
Active rabies vaccine (US-FDA approved)
Drug
Lead sponsor
Kamada, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 3, 2026, 3:53 AM EDT
Completed Phase 3 Interventional

Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies

NCT02912845
View directory record Official record
Conditions
Rabies
Interventions
KamRAB - HRIG
Drug
Lead sponsor
Kamada, Ltd.
Industry
Eligibility
0 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 3, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects

NCT00656097
View directory record Official record
Conditions
Rabies
Interventions
CL184, HRIG, Placebo matching CL184
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
19 Years to 65 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Sep 3, 2026, 3:53 AM EDT